Cholamandalam Investment and Finance reports Q4 consolidated PAT at ₹1,259.54 crore


Cholamandalam Investment and Finance Company Ltd has recorded a consolidated profit after tax for the January-March 2025 quarter at ₹1,259.54 crore, the company said on Saturday.

The city-based company, which is the financial services arm of the diversified conglomerate Murugappa Group, had registered a profit after tax of Rs 1,065.23 crore during the corresponding quarter of last financial year.

For the financial year ending March 31, 2025, the profit after tax surged to ₹4,262.70 crore, from ₹3,420.06 crore registered in the year ago period.

The consolidated total income for the January-March 2025 quarter soared to ₹7,136.91 crore, as compared to ₹5,499.16 crore registered in the year ago period.

For the financial year ending March 31, 2025, the consolidated total income went up to ₹26,152.76 crore from ₹19,419.87 crore registered in the year ago period.

The total disbursements made during the quarter under review grew by 7% to ₹26,417 crore as compared to ₹24,784 crore disbursed during the same quarter of last financial year.

For the year ending March 31, 2025, the total disbursements breached the ₹1 lakh crore mark to touch ₹1,00,869 crore from ₹88,7245 crore registering a growth of 14%, year-on-year basis, the company said.

The Assets Under Management (AUM) as of March 31, 2025 stood at ₹1,99,876 crore, as against ₹1,53,718 crore registered in the year ago period, witnessing a 30% growth.

The Capital Adequacy Ratio (CAR) of the company as of March 31, 2025, was at 19.75% as against the regulatory requirement of 15%.

Tier-I capital was at 14.41% and Tier II capital was at 5.34%. The Common Equity Tier-I Capital was at 13.68% as against a regulatory minimum of 9%, the company said.

The Board of Directors, which met on April 25, has recommended a final dividend of ₹0.70 per share (35%) on the equity shares of the company, subject to the approval of the members.

This is in addition to the interim dividend of ₹1.30 per share (65%) for the financial year 2024-25 declared by the company on January 31, 2025, the company added.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *